MX355107B - Composiciones y metodos para tratar y prevenir infecciones por staphylococcus aureus. - Google Patents

Composiciones y metodos para tratar y prevenir infecciones por staphylococcus aureus.

Info

Publication number
MX355107B
MX355107B MX2016015812A MX2016015812A MX355107B MX 355107 B MX355107 B MX 355107B MX 2016015812 A MX2016015812 A MX 2016015812A MX 2016015812 A MX2016015812 A MX 2016015812A MX 355107 B MX355107 B MX 355107B
Authority
MX
Mexico
Prior art keywords
staphylococcus aureus
treating
methods
compositions
aureus infections
Prior art date
Application number
MX2016015812A
Other languages
English (en)
Other versions
MX2016015812A (es
Inventor
Simard John
Original Assignee
Xbiotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xbiotech Inc filed Critical Xbiotech Inc
Publication of MX2016015812A publication Critical patent/MX2016015812A/es
Publication of MX355107B publication Critical patent/MX355107B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica que comprende un portador farmacéuticamente aceptable y un anticuerpo monoclonal purificado que comprende un dominio variable de cadena pesada que comprende un CDR1, CDR2 y CDR3 de SEQ ID NO: 2, 3 y 4, respectivamente, y un dominio variable de cadena ligera que comprende un CDR1, CDR2 y CDR3 de SEQ ID NO: 7, 8 y 9, respectivamente, en donde el anticuerpo monoclonal se une específicamente a la proteína A de Staphylococcus aureus (spA) con una KD inferior a 1 x 10-10 M mediante su parátopo de la región Fab, en donde el anticuerpo monoclonal es capaz de desplazar inmunoglobulinas IgG de humano a SpA en la bacteria de Staphylococcus aureus mediante sus regiones Fc.
MX2016015812A 2014-06-03 2015-06-03 Composiciones y metodos para tratar y prevenir infecciones por staphylococcus aureus. MX355107B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462007242P 2014-06-03 2014-06-03
US201462041423P 2014-08-25 2014-08-25
US201562115665P 2015-02-13 2015-02-13
PCT/US2015/033902 WO2015187779A1 (en) 2014-06-03 2015-06-03 Compositions and methods for treating and preventing staphylococcus aureus infections

Publications (2)

Publication Number Publication Date
MX2016015812A MX2016015812A (es) 2017-04-25
MX355107B true MX355107B (es) 2018-04-04

Family

ID=54700993

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016015812A MX355107B (es) 2014-06-03 2015-06-03 Composiciones y metodos para tratar y prevenir infecciones por staphylococcus aureus.

Country Status (19)

Country Link
US (7) US9416172B2 (es)
EP (2) EP3154584B1 (es)
JP (4) JP6166000B1 (es)
KR (4) KR20210047355A (es)
CN (2) CN106456763B (es)
AU (2) AU2015271749B2 (es)
BR (1) BR112016028043B1 (es)
CA (1) CA2950840C (es)
CL (1) CL2016003071A1 (es)
ES (1) ES2894867T3 (es)
IL (1) IL248959B (es)
MX (1) MX355107B (es)
MY (1) MY191346A (es)
NZ (1) NZ726911A (es)
PH (2) PH12016502372B1 (es)
RU (2) RU2764981C1 (es)
SG (2) SG11201609487QA (es)
WO (1) WO2015187779A1 (es)
ZA (1) ZA201608604B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6324720B2 (ja) 2010-06-18 2018-05-16 エックスバイオテク, インコーポレイテッドXbiotech, Inc. 関節炎治療
JP6241932B2 (ja) 2010-08-23 2017-12-06 エックスバイオテク, インコーポレイテッドXbiotech, Inc. 腫瘍性疾患のための治療
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
EP2793944A4 (en) 2011-12-23 2015-09-02 Nicholas B Lydon IMMUNOGLOBULINS AND VARIANTS DIRECTED AGAINST PATHOGENIC MICROBES
US9988439B2 (en) 2011-12-23 2018-06-05 Nicholas B. Lydon Immunoglobulins and variants directed against pathogenic microbes
BR112015010125A2 (pt) * 2012-11-06 2017-08-22 Medimmune Llc Anticorpo isolado ou seu fragmento de ligação, composição, ácido nucleico isolado, métodos de determinação da presença de s. aureus em uma amostra de teste, de tratamento de uma infecção por s. aureus em um paciente, de prevenção ou redução da gravidade de sepsia associada a s. aureus em um paciente, de atraso do início de sepsia associada a infecção por s. aureus em um paciente, de prevenção do início de sepsia associada a infecção por s. aureus em um paciente, de redução de carga bacteriana de s. aureus na corrente sanguínea ou coração em um paciente, e de redução da aglutinação bacteriana de s. aureus e/ou formação de lesões tromboembólicas em um paciente
WO2015187779A1 (en) * 2014-06-03 2015-12-10 Xbiotech, Inc. Compositions and methods for treating and preventing staphylococcus aureus infections
RU2757314C2 (ru) 2016-01-22 2021-10-13 Мерк Шарп И Доум Корп. Антитела против фактора свертывания xi
JP7022081B2 (ja) 2016-06-14 2022-02-17 メルク・シャープ・アンド・ドーム・コーポレーション 抗凝固因子ｘｉ抗体
MX2019009798A (es) 2017-02-16 2020-01-30 Xbiotech Inc Tratamiento de la hidradenitis supurativa.
WO2018237010A2 (en) 2017-06-20 2018-12-27 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College VACCINE COMPOSITIONS AGAINST STREPTOCOCCUS AND THEIR METHODS OF USE
WO2019006159A1 (en) * 2017-06-30 2019-01-03 Xbiotech, Inc. COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING STAPHYLOCOCCUS AUREUS INFECTIONS
EP3530282A1 (en) * 2018-02-27 2019-08-28 Diaccurate Therapeutic methods
CN109705213B (zh) * 2018-12-04 2023-04-18 上海长征医院 抗金黄色葡萄球菌毒素抗体及其用途
US20220089706A1 (en) * 2019-01-22 2022-03-24 Clemson University Research Foundation Anti-elastin antibodies and methods of use
KR20210134927A (ko) 2019-02-28 2021-11-11 얀센 바이오테크 인코포레이티드 화농성 한선염의 치료를 위한 항-il-알파 항체
AU2021257453A1 (en) 2020-04-16 2022-11-03 Janssen Biotech, Inc. Treatment of hidradenitis suppurativa

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US5258499A (en) 1988-05-16 1993-11-02 Vestar, Inc. Liposome targeting using receptor specific ligands
DE3825429C2 (de) 1988-07-27 1994-02-10 Biotest Pharma Gmbh Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen Immunglobulin-Präparates mit hohem IgM-Gehalt
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5077391A (en) 1989-12-01 1991-12-31 Raison Robert L Purification of immunoglobulin M
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5111074A (en) 1990-07-26 1992-05-05 Regents Of The University Of Minnesota Multi-input compound function complementary noise-immune logic
US5112952A (en) 1990-09-28 1992-05-12 Pierce Chemical Company Composition and method for isolation and purification of Immunoglobulin M
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
ATE363532T1 (de) 1991-03-01 2007-06-15 Dyax Corp Verfahren zur herstellung bindender miniproteine
DE69233367T2 (de) 1991-04-10 2005-05-25 The Scripps Research Institute, La Jolla Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
WO1994009818A1 (en) 1992-10-30 1994-05-11 The Regents Of The University Of California Method for stimulating production of variable region gene family restricted antibodies through b-cell superantigen vaccination
US5545721A (en) 1992-12-21 1996-08-13 Ophidian Pharmaceuticals, Inc. Conjugates for the prevention and treatment of sepsis
US5770208A (en) 1996-09-11 1998-06-23 Nabi Staphylococcus aureus B-linked hexosamine antigen
EP0835880A1 (de) 1996-10-14 1998-04-15 Rotkreuzstiftung Zentrallaboratorium Blutspendedienst Srk Verfahren zur Herstellung eines IgM Präparates für die intravenöse Applikation
EP2180007B2 (en) 1998-04-20 2017-08-30 Roche Glycart AG Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US8142780B2 (en) 1998-08-20 2012-03-27 Strox Biopharmaceuticals, Llc Anti-bacterial antibodies
US6322788B1 (en) 1998-08-20 2001-11-27 Stanley Arthur Kim Anti-bacterial antibodies and methods of use
US6692739B1 (en) 1998-08-31 2004-02-17 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
CA2785941C (en) 2000-10-06 2017-01-10 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
US20030003097A1 (en) 2001-04-02 2003-01-02 Idec Pharmaceutical Corporation Recombinant antibodies coexpressed with GnTIII
US7169903B2 (en) 2001-12-21 2007-01-30 Biosynexus Incorporated Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria
WO2007024249A2 (en) 2004-11-10 2007-03-01 Macrogenics, Inc. Engineering fc antibody regions to confer effector function
US20090061485A1 (en) 2004-12-22 2009-03-05 Chugai Seiyaku Kabushiki Kaisha Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited
ES2592271T3 (es) 2005-03-31 2016-11-29 Chugai Seiyaku Kabushiki Kaisha Métodos de producción de polipéptidos mediante la regulación de la asociación de los polipéptidos
AU2006239851B2 (en) 2005-04-26 2011-06-16 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
CN101074263B (zh) * 2006-05-17 2011-07-06 上海抗体药物国家工程研究中心有限公司 一种重组抗proteinA单克隆抗体及其制备方法和用途
US7488807B2 (en) 2006-11-22 2009-02-10 3M Innovative Properties Company Antibody with protein A selectivity
WO2008127457A2 (en) * 2006-12-06 2008-10-23 Repligen Corporation Nucleic acids encoding recombinant protein a
EP3636668A3 (en) 2007-04-23 2020-07-29 Sudhir Paul Immunoglobulins directed to bacterial viral and endogenous polypeptides
CN101874041B (zh) 2007-09-26 2013-06-19 中外制药株式会社 抗体恒定区修饰体
JP2011519974A (ja) * 2008-05-12 2011-07-14 ストロックス バイオファーマスーティカルズ，エルエルシー 黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）に特異的な抗体製剤
CN101339197B (zh) * 2008-07-30 2012-07-04 广州康盛生物科技有限公司 葡萄球菌蛋白a定量检测试剂盒及定量检测方法
US20100092470A1 (en) 2008-09-22 2010-04-15 Icb International, Inc. Antibodies, analogs and uses thereof
US9013699B2 (en) 2009-11-09 2015-04-21 Cantwell G. Carson Vaccine testing system
CA2794708C (en) 2010-03-29 2021-11-16 Zymeworks Inc. Antibodies with enhanced or suppressed effector function
JP2013523818A (ja) * 2010-04-05 2013-06-17 ザ・ユニバーシティー・オブ・シカゴ 免疫反応のエンハンサーとしてのプロテインＡ（ＳｐＡ）抗体に関連する組成物および方法
CN103492565B (zh) 2011-02-25 2021-01-29 中外制药株式会社 FcγRIIb特异性Fc抗体
WO2013009967A2 (en) 2011-07-12 2013-01-17 Xbiotech, Inc. Identifying affinity-matured human antibodies
BR112014003315A2 (pt) * 2011-08-15 2017-03-01 Univ Chicago composições e métodos relacionados a anticorpos para a proteína a estafilocócica
IN2014CN04961A (es) 2011-12-05 2015-09-18 Igenica Biotherapeutics Inc
EP2793944A4 (en) * 2011-12-23 2015-09-02 Nicholas B Lydon IMMUNOGLOBULINS AND VARIANTS DIRECTED AGAINST PATHOGENIC MICROBES
EP2705852A1 (en) * 2012-09-06 2014-03-12 Université de Lausanne An immunogenic composition against Staphylococcus aureus comprising an inactivated recombinant non-pathogenic bacterium
BR112015010125A2 (pt) * 2012-11-06 2017-08-22 Medimmune Llc Anticorpo isolado ou seu fragmento de ligação, composição, ácido nucleico isolado, métodos de determinação da presença de s. aureus em uma amostra de teste, de tratamento de uma infecção por s. aureus em um paciente, de prevenção ou redução da gravidade de sepsia associada a s. aureus em um paciente, de atraso do início de sepsia associada a infecção por s. aureus em um paciente, de prevenção do início de sepsia associada a infecção por s. aureus em um paciente, de redução de carga bacteriana de s. aureus na corrente sanguínea ou coração em um paciente, e de redução da aglutinação bacteriana de s. aureus e/ou formação de lesões tromboembólicas em um paciente
WO2015187779A1 (en) * 2014-06-03 2015-12-10 Xbiotech, Inc. Compositions and methods for treating and preventing staphylococcus aureus infections

Also Published As

Publication number Publication date
US10577410B2 (en) 2020-03-03
KR20170078846A (ko) 2017-07-07
JP6166000B1 (ja) 2017-07-19
US20170015734A1 (en) 2017-01-19
US20150344548A1 (en) 2015-12-03
PH12016502372A1 (en) 2017-02-20
ES2894867T3 (es) 2022-02-16
WO2015187779A1 (en) 2015-12-10
CN106456763B (zh) 2018-03-13
KR102015451B1 (ko) 2019-08-28
AU2018200886B2 (en) 2019-06-06
PH12018501429A1 (en) 2019-02-27
EP3154584A1 (en) 2017-04-19
EP3154584A4 (en) 2018-06-06
CA2950840A1 (en) 2015-12-10
JP2017214388A (ja) 2017-12-07
CL2016003071A1 (es) 2017-09-15
RU2636780C1 (ru) 2017-11-28
EP3970747A3 (en) 2022-10-05
MY191346A (en) 2022-06-17
CN108404128A (zh) 2018-08-17
KR20210047355A (ko) 2021-04-29
AU2015271749B2 (en) 2018-03-01
EP3154584B1 (en) 2021-08-04
AU2018200886A1 (en) 2018-02-22
KR20170007825A (ko) 2017-01-20
CN106456763A (zh) 2017-02-22
US11370831B2 (en) 2022-06-28
NZ726911A (en) 2023-01-27
US11773157B2 (en) 2023-10-03
PH12016502372B1 (en) 2017-02-20
US9783598B2 (en) 2017-10-10
JP2022105178A (ja) 2022-07-12
JP2017522275A (ja) 2017-08-10
SG10201703965SA (en) 2017-06-29
BR112016028043B1 (pt) 2023-12-12
US20190127449A1 (en) 2019-05-02
US20200131252A1 (en) 2020-04-30
KR101753553B1 (ko) 2017-07-03
IL248959B (en) 2022-01-01
US10214581B2 (en) 2019-02-26
US20160279243A1 (en) 2016-09-29
JP6672221B2 (ja) 2020-03-25
US9486523B2 (en) 2016-11-08
AU2015271749A1 (en) 2016-12-01
SG11201609487QA (en) 2016-12-29
IL248959A0 (en) 2017-01-31
JP2020073548A (ja) 2020-05-14
BR112016028043A2 (pt) 2017-10-24
KR20190100471A (ko) 2019-08-28
ZA201608604B (en) 2018-05-30
US9416172B2 (en) 2016-08-16
CA2950840C (en) 2023-09-26
EP3970747A2 (en) 2022-03-23
RU2764981C1 (ru) 2022-01-24
MX2016015812A (es) 2017-04-25
US20220251175A1 (en) 2022-08-11
US20170349648A1 (en) 2017-12-07

Similar Documents

Publication Publication Date Title
PH12018501429A1 (en) Compositions and methods for treating and preventing staphylococcus aureus infections
MX2022003891A (es) Anticuerpos anti-muc16 y sus usos.
DK3458478T3 (da) Anti-pd-1- og anti-lag3-antistoffer til cancerbehandling
EA201691488A1 (ru) Молекулы антител против pd-1 и их применения
DK3368572T3 (da) Anti-pd-1-antistoffer og -sammensætninger
BR112017000664A2 (pt) anticorpo anti-pd-1 e seu uso
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
EP4249515A3 (en) Humanized or chimeric cd3 antibodies
TR201817932T4 (tr) Staphylococcus aureus alfa toksi̇ni̇ni̇ spesi̇fi̇k olarak bağlayan anti̇korlar ve kullanim yöntemleri̇
WO2014151680A8 (en) Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies
TW201613575A (en) Treatment of polybacterial infections
IL246160A0 (en) Antibodies directed against the toxin (lukgh (lukab) of staphylococcus aureus and antibody sequences
CO2017001087A2 (es) Anticuerpos anti proteína similar a angiopoyetina 4
EP3291837A4 (en) MONOCLONAL ANTIBODY COCOA TAILS FOR THE TREATMENT OF EBOLA INFECTIONS
IL291266A (en) Preparations and methods for treating infections
UY36261A (es) Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso
EP3183002A4 (en) Monoclonal antibodies for treatment of microbial infections
MX2015008486A (es) Composiciones y metodos para tratar infecciones bacterianas.
EP3226902A4 (en) IMMUNOGLOBULIN COMPOSITIONS FOR HORSES AND USES FOR THE TREATMENT OF FILOVIRUS-MEDIATED ILLNESSES
EP3190893A4 (en) Compositions and methods for treating and preventing bacterial infections
BR112017011076A2 (pt) métodos e composições para prevenir ou reduzir infecções de plantas cultivadas por agentes patogênicos fúngicos e bacterianos
MX2015009819A (es) Anticuerpo humano especifico a metapneumovirus humano, o fragmento de union al antigeno del mismo.
EP3592770A4 (en) HUMAN MONOCLONAL ANTIBODIES AGAINST LUKAB TOXIN BY STAPHYLOCOCCUS AUREUS
EP3311419A4 (en) SOURCE FARM FILTER FIELD EFFECT TRANSISTOR
EP3116540A4 (en) Compositions and methods for treating, including preventing, parvovirus infections and related diseases

Legal Events

Date Code Title Description
FG Grant or registration